Cargando…
A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted
Previous studies of SARS-CoV-2 viral infection suggest that both the humoral and cytotoxic arms of the immune system are weak in patients with severe COVID-19 disease when compared to mild disease. A cytokine storm is also induced in severe disease. IL-15 has been shown to support the cytotoxic arm...
Autor principal: | Wilz, Stephen W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583616/ https://www.ncbi.nlm.nih.gov/pubmed/33199178 http://dx.doi.org/10.1016/j.cytogfr.2020.10.005 |
Ejemplares similares
-
IL-2, IL-15 and IL-21 expand T cells for targeted adoptive therapy
por: Liu, Zhenjiang, et al.
Publicado: (2015) -
Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted
por: Panda, Aditya K., et al.
Publicado: (2021) -
Synergy of IL-21 and IL-15 in regulating CD8(+) T cell expansion and function
por: Zeng, Rong, et al.
Publicado: (2005) -
IL-15 in the Combination Immunotherapy of Cancer
por: Waldmann, Thomas A., et al.
Publicado: (2020) -
IL-15/IL-15Rα in SJS/TEN: Relevant Expression of IL15 and IL15RA in Affected Skin
por: Bellón, Teresa, et al.
Publicado: (2022)